Malik et al. [17], after highlighting the overexpression of Eg5 to cancer cells and its importance as a target of anticancer agents, modified monastrol, an already known Eg5 inhibitor, with amino acids cysteine and proline with an aim to produce powerful Eg5 inhibitors (Figure 19). This evidence concerns the gene KIF11 and cancer.